Regulation & News

BPC-157 and the FDA: What the July 2026 Advisory Committee Vote Actually Means

Published October 20, 2026 · Last reviewed October 20, 2026 · 11 linked sources · How we source

Status: Not FDA-approved · Recommended (non-binding) for 503A Bulks List · Not yet listed

On July 23, 2026, a Food and Drug Administration advisory committee voted 8–6, with one abstention, in favor of adding BPC-157 to the list of bulk drug substances that pharmacies may use in compounding. Headlines called it a win for the peptide. The vote matters, but it changed far less than many social media posts suggest. This explainer walks through what the committee was asked, how it voted, what FDA's own scientists said, and what still has to happen before anything changes legally.

The short version

• BPC-157 is not an FDA-approved drug. No vote in July changed that.
• The Pharmacy Compounding Advisory Committee (PCAC) voted 8–6, with one abstention, to recommend BPC-157 for the 503A Bulks List, the list of bulk ingredients that state-licensed compounding pharmacies may use under federal law (ABC News).
• The vote is non-binding. FDA must decide whether to accept it and, under the usual process, complete notice-and-comment rulemaking before pharmacies could legally compound the substance (AJMC).
• FDA's own briefing documents recommended against listing either BPC-157 (free base) or BPC-157 acetate (FDA meeting materials).

What the committee was actually asked

The PCAC is an outside panel that advises FDA on compounding questions. At its July 23–24, 2026 meeting, the agenda for the first day covered four groups of peptides being considered for the 503A Bulks List: BPC-157 (free base and acetate), KPV, TB-500, and MOTS-c. FDA's agenda listed the specific use it had reviewed for each. For BPC-157, the use evaluated was ulcerative colitis (FDA meeting page).

That detail matters. The committee was not asked whether BPC-157 "heals injuries," improves recovery, or slows aging, the claims most often made online. It was asked about one bulk ingredient, for one condition FDA chose to review, under one section of the compounding law.

FDA's briefing document also notes some background that rarely makes it into coverage. BPC-157 is also known as Bepecin or PL-14736, and is reported to be a peptide of 15 amino acids. FDA said the two nominations it received, from Wells Pharmacy Network and LDT Health Solutions, gave inconsistent information about whether they meant the acetate salt or the free base. FDA treats those as different active ingredients, so it evaluated both on its own initiative. The nominations themselves had been withdrawn, and FDA proceeded with the evaluation at its discretion (FDA briefing document).

How the vote went

ABC News reported that the committee voted 8–6 in favor, with one abstention, and that BPC-157 was the first of seven peptides reviewed over the two days (ABC News). By the end of the meeting, the panel had recommended six of the seven: BPC-157, KPV, TB-500, MOTS-c, Semax and epitalon. The one it rejected was emideltide (also called delta sleep-inducing peptide, or DSIP), by a 7–6 vote with one abstention (AJMC).

According to ABC News, members who voted yes generally believed the risks were minimal. Members who voted no tended to worry about safety and effectiveness, and about creating a false impression that BPC-157 had been held to the same standard as an FDA-approved drug (ABC News).

The panel's makeup was itself part of the story. AJMC reported that the reconstituted committee roster included more health professionals who prescribe, produce, or promote peptides than earlier versions of the panel, which had historically been made up mainly of academics and researchers, and that this drew conflict-of-interest scrutiny (AJMC).

What FDA's scientists recommended

In the meeting materials, FDA's "points to consider" were blunt: FDA proposed that BPC-157 (free base) not be included on the 503A Bulks List, and that BPC-157 acetate not be included either (FDA meeting materials). AJMC reported that FDA scientists opposed adding any of the seven substances under review, which made the committee's votes unusual (AJMC).

FDA's broader safety concerns are on the public record. On its page listing bulk substances that may present significant safety risks, FDA now places BPC-157 under "Bulk drug substances nominated but withdrawn." Its entry says compounded BPC-157 may pose a risk of immunogenicity (an unwanted immune response) for certain routes of administration, may have complexities with peptide-related impurities and characterization of the active ingredient, and that FDA identified "no, or only limited, safety-related information" for the proposed routes, so "the agency lacks sufficient information to know whether the drug would cause harm when administered to humans" (FDA).

Note the wording. FDA is not saying BPC-157 is proven harmful. It is saying the data do not exist to know either way. Moving off the "Category 2" list because nominators withdrew is not a safety clearance.

What the human evidence looks like

Most BPC-157 research is in animals and cell cultures. On human data, the picture presented to the committee was thin. AJMC summarized FDA's briefing as finding that the available studies, including five trials of BPC-157, were short, small, and insufficient to establish safety or effectiveness for the indications reviewed (AJMC). The consumer group Public Citizen, which testified against listing BPC-157, described the five studies as small, enrolling between two and 26 participants, and very short (Public Citizen testimony).

ABC News, summarizing the meeting, put it simply: there is very little human clinical trial data supporting the effectiveness or safety of these peptides, and FDA staff scientists highlighted a general lack of quality data (ABC News).

A committee vote is not evidence. Whatever FDA ultimately decides about compounding access, it would not turn small, short studies into proof that BPC-157 works for gut healing, injuries or anything else. Anyone reading claims about BPC-157 should ask the same question this site asks: which human trial, how many people, how long, and measuring what?

Why a "bulks list" vote is not approval

To see why the vote is narrower than it sounds, it helps to know how compounding law works. Under section 503A of the Federal Food, Drug, and Cosmetic Act, a licensed pharmacist in a state-licensed pharmacy (or a licensed physician) can compound drugs for an identified individual patient based on a valid prescription. Drugs compounded under all of 503A's conditions are exempt from FDA's new-drug approval requirements, among others (FDA).

But 503A limits which bulk ingredients can be used. Generally, an ingredient must have an applicable USP or National Formulary monograph, be a component of an FDA-approved drug, or appear on a list FDA develops through regulations (FDA). BPC-157 is not a component of any FDA-approved drug, which is why the bulks list is the route under discussion.

So even in the best case for supporters, listing would mean that a pharmacy could compound BPC-157 for an individual patient with a prescription. It would not mean FDA found the product safe or effective. In FDA's own words, compounded drugs "are not FDA-approved," which means FDA "does not verify the safety, effectiveness or quality of compounded drugs before they are marketed" (FDA Q&A). (For more on the two compounding pathways, see our explainer, 503A vs 503B Compounding Pharmacies, Explained.)

What has happened since July

The next step came in October. On October 14, 2026, a notice titled "Interim Access Policy for Compounding Using Certain Peptides" from HHS/FDA was received for White House regulatory review, according to the Office of Management and Budget's public review listing (Reginfo.gov). Reuters reported that the filing gave no details of the policy, while the Associated Press, citing two people familiar with the matter, reported that it would allow pharmacies to make some popular peptides, including BPC-157 (Reuters via Yahoo News).

As of this writing, the policy text has not been published, and BPC-157 has not been added to the 503A Bulks List. We cover what is and is not known in FDA's Interim Peptide Compounding Policy: What We Know So Far.

Status at a glance

What this means for you

If you have seen BPC-157 promoted as "FDA-backed" after the July vote, that is not accurate. An advisory committee recommended, against FDA staff advice, that it be considered for a compounding list. FDA has not acted on that recommendation through a final rule, and the agency's own documented position is that it lacks the data to know whether BPC-157 is safe in humans.

Products sold online as "research peptides" are outside both the approval system and the compounding system. This site does not link to, or help anyone find, such sellers. If you are considering any peptide, talk to a licensed clinician about the evidence and the risks. We will update this page when FDA publishes its policy or takes rulemaking action.